SBEM (Brazilian Society of Endocrinology and Metabology), Febrasgo (Brazilian Federation of Gynecology and Obstetrics Associations) and SBC (Brazilian Society of Cardiology) published a joint note restricting the use of testosterone in women.
According to the three medical entities, “the prescription of must be strictly restricted to the only formally recognized indication – TDSH), after adequate clinical evaluation, being potentially harmful when used without indication, based on isolated dosages or with non-therapeutic objectives.”
The statement warns of side effects, some of which are serious. “The use of testosterone outside of its sole indication in women increases the risk of adverse events, including: virilizing effects such as acne, hair loss, hair growth, enlargement of the clitoris and irreversible deepening of the voice, toxicity and liver tumors, psychological and psychiatric changes, infertility and potential cardiovascular repercussions such as high blood pressure, arrhythmias, embolisms, thrombosis, heart attack, stroke and increased mortality, in addition to changes in other tests. laboratory tests, such as cholesterol and triglycerides.”
The note also highlights that Anvisa has not approved any formulation of testosterone for use in women and that the regulatory agency also does not recognize “the use of testosterone for aesthetic purposes, improving body composition, physical performance, disposition or anti-aging.”
